Search
Vaccines Treatment Options in Austin, TX
A collection of 78 research studies where Vaccines is the interventional treatment. These studies are located in the Austin, TX. Vaccines is used for conditions such as Influenza, COVID-19 and Hepatitis B.
1 - 12 of 78
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Depressive disorder Clinical Study
Recruiting
A clinical study for people that suffer with Depressive disorder
Conditions:
Depressive disorder
Phase 3 Adolescent Study for SARS-CoV-2 rS Variant Vaccines
Completed
This study is a large-scale investigation (Phase 3) into a new booster shot designed specifically for teenagers. The booster targets a particular variant of COVID-19, Omicron XBB.1.5. The main focus is on safety: researchers want to see if this new booster is safe for teenagers who have already received two doses of the Pfizer or Moderna mRNA COVID-19 vaccines. To ensure a fair comparison, the study will use a double-blind approach. This means two groups of teenagers will receive booster shots,... Read More
Gender:
ALL
Ages:
Between 11 years and 18 years
Trial Updated:
06/25/2025
Locations: Benchmark Research, Austin, Texas +5 locations
Conditions: COVID-19
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA Vaccines
Completed
This is an open-label Phase 3 study evaluating the immunogenicity and safety of Novavax vaccine(s) with Matrix-M™ adjuvant (ancestral strain NVX-CoV2373 and an alternative strain and/or multivalent Novavax vaccine) as booster doses following a series of primary and booster doses of authorized/approved mRNA vaccines followed by a single booster dose of NVX-CoV2373 in the Novavax 2019nCoV-307 study (NCT05463068).
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
06/25/2025
Locations: Benchmark Research, Austin, Texas +4 locations
Conditions: COVID-19
Study of mRNA-1010 Seasonal Influenza Vaccine in Adults
Completed
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/23/2025
Locations: Tekton Research - Austin - PPDS, Austin, Texas +10 locations
Conditions: Seasonal Influenza
A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age
Completed
The purpose of this study is to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1083 as compared with active control, co-administered licensed influenza and severe acute respiratory syndrome coronavirus 2 (SARS CoV 2) vaccines, in 2 independent age-group sub-study cohorts, healthy adults 65 years and older (Cohort A) and healthy adults 50 to \<65 years of age (Cohort B).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
06/23/2025
Locations: AES - DRS - Optimal Research Texas - Austin, Austin, Texas +21 locations
Conditions: SARS-CoV-2, Influenza
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Velocity Clinical Research - Abilene, Abilene, Texas +13 locations
Conditions: SARS-CoV2, COVID-19
IBRX-042 In Participants With HPV-Associated Tumors
Recruiting
The goal of this clinical trial is to determine the maximum tolerated dose and to find out the side effects of a drug called IBRX-042 at different dose levels in patients with recurrent or progressive Human Papillomavirus (HPV) associated tumors. The main questions it aims to answer are:
* What is the maximum tolerated dose of IBRX-042?
* How well does the study drug treat cancer?
* What effects the study drug may have on the human body and cancer?
Participants will receive IBRX-042 at one of... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/22/2025
Locations: Texas Oncology Austin Central, Austin, Texas +1 locations
Conditions: HPV-Related Carcinoma
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
Completed
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
Gender:
ALL
Ages:
65 years and above
Trial Updated:
05/22/2025
Locations: Optimal Research, Austin, Texas +2 locations
Conditions: Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
A Study of Safety and Immune Response to Different Doses of a Cytomegalovirus Vaccine in Healthy Adults
Completed
The purpose of this study is to assess the safety, reactogenicity and immune response of the candidate CMV recombinant protein subunit (CMVsu) vaccine consisting of a combination of glycoproteins B (gB) and pentamer antigens adjuvanted, regardless of baseline CMV sero-status. This FTiH study will be conducted in healthy adults 18 to 50 years of age, in which the 4 dose levels of the vaccine will be administered in a step-wise dose escalation manner, based upon safety adjudication.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
05/12/2025
Locations: GSK Investigational Site, Austin, Texas +2 locations
Conditions: Cytomegalovirus Infections
A Safety and Immune Response Study to Evaluate Varying Doses of an mRNA Vaccine Against Coronavirus Disease 2019 (COVID-19) in Healthy Adults
Completed
The purpose of this study is to evaluate the safety, reactogenicity and immune responses of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA-CR-04 vaccine construct when administered in healthy adults previously vaccinated with SARS-CoV-2 mRNA vaccines.
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
05/08/2025
Locations: GSK Investigational Site, Austin, Texas
Conditions: COVID-19
A Study to Evaluate a Modified RNA Vaccine Against Influenza in Adults 18 Years of Age or Older
Completed
This is a Phase 3, randomized, observer-blinded study to evaluate the efficacy, safety, tolerability, and immunogenicity of a single dose of a quadrivalent influenza modRNA vaccine compared to licensed inactivated influenza vaccine in healthy adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/18/2025
Locations: Elligo Clinical Research Center, Austin, Texas +30 locations
Conditions: Influenza, Human
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza messenger ribonucleic acid (mRNA) Vaccine MRT5413 compared to an active control (QIVstandard-dose (SD), QIV high-dose (HD) \[adults ≥ 65 years of age only\], or quadrivalent recombinant influenza vaccine (RIV4)) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Elligo Health Research, Inc. Site Number : 8400002, Austin, Texas +2 locations
Conditions: Influenza Immunization
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older
Completed
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular (IM) injection of up to 3 dose levels of Quadrivalent Influenza mRNA Vaccine MRT5410 compared to an active control (QIV SD, QIV HD \[adults ≥ 65 years of age only\], or RIV4) in adults 18 years of age and older.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/14/2025
Locations: Elligo Health Research, Inc. Site Number : 8400037, Austin, Texas +5 locations
Conditions: Influenza Immunization
1 - 12 of 78